Related Experiment Video

Updated: Jan 29, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K

Adverse Respiratory Reactions to Tyrosine Kinase Inhibitors: A Disproportionality Analysis of Spontaneous Reports

Ilaria Ammendolia1, Carmen Mannucci2, Emanuela Esposito1

  • 1Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.

Life (Basel, Switzerland)
|January 28, 2026
PubMed
Abstract

Insights

Dasatinib and bosutinib, tyrosine kinase inhibitors (TKIs) for chronic myelogenous leukemia (CML), are linked to significant pulmonary risks like pleural effusion and pulmonary arterial hypertension. Early diagnosis and cautious prescribing are crucial for patients with CML and lung conditions.

Area of Science:

  • Pharmacology
  • Oncology
  • Pulmonology

Background:

  • Tyrosine kinase inhibitors (TKIs) are vital for chronic myelogenous leukemia (CML) treatment.
  • Existing pharmacovigilance data on TKI-associated pulmonary toxicity is inconsistent.
  • Pulmonary adverse events may limit the clinical utility of approved TKIs.

Purpose of the Study:

  • To investigate the pulmonary risk profile of specific TKIs used in CML therapy.
  • To analyze adverse event reports for asciminib, bosutinib, dasatinib, imatinib, nilotinib, and ponatinib.
  • To clarify the association between TKIs and respiratory disorders.

Main Methods:

  • Utilized the European database EudraVigilance for adverse event data (2020-2024).
  • Focused on reports from European countries and the United Kingdom.
  • Employed disproportionality analysis to compare TKI-related adverse reactions.

Main Results:

  • Dasatinib and bosutinib showed the most frequent alerts for pleural effusion (PE) and pulmonary arterial hypertension (PAH).
  • Dasatinib prescription correlated with higher occurrences of PE and PAH.
  • Bosutinib use also presented a significant risk for PAH, particularly in women, despite lower PE frequency.

Conclusions:

  • Timely diagnosis of TKI-induced respiratory disorders, especially from dasatinib and bosutinib, is essential.
  • Caution is advised when prescribing these TKIs to CML patients with pre-existing pulmonary conditions.
  • Further monitoring for pulmonary toxicities associated with TKIs is warranted.
Keywords:
asciminibbosutinibchronic myelogenous leukemiadasatinibimatinibnilotinibpleural effusionponatinibpulmonary arterial hypertensiontyrosine kinase inhibitors

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.3K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.3K

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
518
Spontaneity02:21

Spontaneity

A spontaneous process is one that occurs naturally under certain conditions. A nonspontaneous process, on the other hand, will not take place unless it is “driven” by the continual input of energy from an external source. Processes have a natural tendency to occur in one direction under a given set of conditions. Water will naturally flow downhill (spontaneous process), but uphill flow (nonspontaneous process) requires outside intervention such as the use of a pump. Iron exposed to...
29.7K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.1K
Half-life of a Reaction02:42

Half-life of a Reaction

The half-life of a reaction (t1/2) is the time required for one-half of a given amount of reactant to be consumed. In each succeeding half-life, half of the remaining concentration of the reactant is consumed. For example, during the decomposition of hydrogen peroxide, during the first half-life (from 0.00 hours to 6.00 hours), the concentration of H2O2 decreases from 1.000 M to 0.500 M. During the second half-life (from 6.00 hours to 12.00 hours), the concentration decreases from 0.500 M to...
38.9K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K